Login / Signup

Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity.

Kuan Rong ChanXiaohui WangWilfried A A SaronEsther Shuyi GanHwee Cheng TanDarren Z L MokSummer Li-Xin ZhangYie Hou LeeCui LiangLimin WijayaSujoy GhoshYin Bun CheungSteven R TannenbaumSoman N AbrahamAshley L St JohnJenny G H LowEng Eong Ooi
Published in: Nature microbiology (2016)
Vaccination has achieved remarkable successes in the control of childhood viral diseases. To control emerging infections, however, vaccines will need to be delivered to older individuals who, unlike infants, probably have had prior infection or vaccination with related viruses and thus have cross-reactive antibodies against the vaccines. Whether and how these cross-reactive antibodies impact live attenuated vaccination efficacy is unclear. Using an open-label randomized trial design, we show that subjects with a specific range of cross-reactive antibody titres from a prior inactivated Japanese encephalitis vaccination enhanced yellow fever (YF) immunogenicity upon YF vaccination. Enhancing titres of cross-reactive antibodies prolonged YF vaccine viraemia, provoked greater pro-inflammatory responses, and induced adhesion molecules intrinsic to the activating Fc-receptor signalling pathway, namely immune semaphorins, facilitating immune cell interactions and trafficking. Our findings clinically demonstrate antibody-enhanced infection and suggest that vaccine efficacy could be improved by exploiting cross-reactive antibodies.
Keyphrases
  • physical activity
  • signaling pathway
  • sars cov
  • young adults
  • diabetic rats
  • cystic fibrosis
  • high glucose
  • candida albicans